Back to Search
Start Over
Severe eosinophilic granulomatosis with polyangiitis responding to a combination of rituximab and mepolizumab.
- Source :
-
The American journal of the medical sciences [Am J Med Sci] 2023 Jan; Vol. 365 (1), pp. 93-98. Date of Electronic Publication: 2022 Aug 12. - Publication Year :
- 2023
-
Abstract
- Eosinophilic granulomatosis with polyangiitis (EGPA), formerly known as Churg-Strauss Syndrome, is a multisystem antineutrophil cytoplasmic antibody (ANCA) positive vasculitis, characterized by the presence of chronic rhinosinusitis, asthma and prominent peripheral blood eosinophilia. Although the most commonly involved organ is the lung, followed by the skin, EGPA can affect any organ system. Herein, we present the complicated case of an 18-year-old male patient with severe life-threatening EGPA, with central nervous system, cardiac and gasterointestinal involvement, which was resistant to initial treatment with glucocorticoids and cyclophosphamide. The patient responded well, achieving complete remission after the addition of rituximab and mepolizumab to glucocorticoids and cyclophosphamide.<br />Competing Interests: Declaration of Competing Interest There are no conflict sof interest regarding this manuscript.<br /> (Copyright © 2022 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights reserved.)
- Subjects :
- Male
Humans
Adolescent
Rituximab therapeutic use
Glucocorticoids
Cyclophosphamide therapeutic use
Antibodies, Antineutrophil Cytoplasmic
Churg-Strauss Syndrome complications
Churg-Strauss Syndrome drug therapy
Granulomatosis with Polyangiitis complications
Granulomatosis with Polyangiitis drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1538-2990
- Volume :
- 365
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- The American journal of the medical sciences
- Publication Type :
- Academic Journal
- Accession number :
- 35970248
- Full Text :
- https://doi.org/10.1016/j.amjms.2022.07.007